In 1998, Trastuzumab was the first HER2 targeted treatment to be approved for HER2-positive metastatic breast cancer and since then its use has expanded to treat all stages of breast cancer and many novel anti-HER2 therapies have followed [174]. This evidence concerns the gene ERBB2 and breast carcinoma.